Optimer's Early Sales Of Dificid Topping Analyst Projections
This article was originally published in The Pink Sheet Daily
The anti-clostridial antibiotic, approved by FDA in May, is seeing rapid early adoption by hospital formularies.
You may also be interested in...
Cubist Pharmaceuticals will strengthen its position in the challenging antibiotic market with the acquisitions of two rivals, Optimer Pharmaceuticals and Trius Therapeutics. But it was Cubist’s current strength that allowed it to get those deals done on favorable, risk-sharing terms.
Cubist will rely on its experience in infectious disease to drive growth of Dificid for Clostridium difficile infection and to launch tedizolid for skin infections, but the commercial market for new antibiotics is daunting and re-creating the success of Cubicin won’t be easy.
A year after FDA approval of its antibiotic Dificid, the Optimer board has ousted its chairman and at least two other top executives.